Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

Sanofi36 enrolled

Overview

1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Noonan Syndrome

Interventions

MAXOMAT ®, biosynthetic growth hormoneDRUG

2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration

Eligibility

Sex: ALLMin age: 3 YearsMax age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children and adolescents with Noonan's syndrome with a height \< -2 SD and no progressive cardiopathy Exclusion Criteria: * Age \< 3 years * Height ≥ -2 SD The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Paris, France

Outcomes

Primary Outcomes

Evaluation of height : gain in height and rate of growth

Time frame: at each visit (every 3 months) or every 6 months

Secondary Outcomes

Clinical and laboratory test safety

Time frame: every 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.